Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
In the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut. Apnimed
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.